{"disease":{"id":"nsclc-adenocarcinoma","name":"nsclc adenocarcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05550961","title":"APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch","phase":"","overall_status":"RECRUITING","enrollment_count":1200,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT05379985","title":"Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":754,"lead_sponsor_name":"Revolution Medicines, Inc.","has_results":false},{"nct_id":"NCT06040541","title":"Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":604,"lead_sponsor_name":"Revolution Medicines, Inc.","has_results":false},{"nct_id":"NCT02864992","title":"Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":337,"lead_sponsor_name":"EMD Serono Research & Development Institute, Inc.","has_results":true},{"nct_id":"NCT02900664","title":"A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":283,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07277413","title":"A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"IDEAYA Biosciences","has_results":false},{"nct_id":"NCT07223047","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":252,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT06710132","title":"Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"EMD Serono Research & Development Institute, Inc.","has_results":false},{"nct_id":"NCT06682793","title":"A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"A2 Biotherapeutics Inc.","has_results":false},{"nct_id":"NCT06792435","title":"XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Evopoint Biosciences Inc.","has_results":false},{"nct_id":"NCT05462717","title":"Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":222,"lead_sponsor_name":"Revolution Medicines, Inc.","has_results":false},{"nct_id":"NCT07219251","title":"Engagement of Veterans With Lung Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":194,"lead_sponsor_name":"Palo Alto Veterans Institute for Research","has_results":false},{"nct_id":"NCT07374419","title":"Atamparib in Patients With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":178,"lead_sponsor_name":"Nerviano Medical Sciences (Shanghai) Ltd.","has_results":false},{"nct_id":"NCT05933265","title":"Study of LP-184 in Patients With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":175,"lead_sponsor_name":"Lantern Pharma Inc.","has_results":false},{"nct_id":"NCT02387216","title":"A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":153,"lead_sponsor_name":"Elevation Oncology","has_results":true},{"nct_id":"NCT03549000","title":"A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":127,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07002788","title":"Comparison Paravertebral and Serratus Anterior Plane Block in Video-assisted Thoracoscopic Surgery.","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":122,"lead_sponsor_name":"Hacettepe University","has_results":false},{"nct_id":"NCT07435038","title":"Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Betta Pharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT03184571","title":"Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":99,"lead_sponsor_name":"BerGenBio ASA","has_results":true},{"nct_id":"NCT04772989","title":"A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Arcus Biosciences, Inc.","has_results":false},{"nct_id":"NCT02133196","title":"T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":85,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07410494","title":"Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":85,"lead_sponsor_name":"Essen Biotech","has_results":false},{"nct_id":"NCT03252938","title":"Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":83,"lead_sponsor_name":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","has_results":false},{"nct_id":"NCT04114136","title":"Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":72,"lead_sponsor_name":"Dan Zandberg","has_results":false},{"nct_id":"NCT03636685","title":"Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT06951399","title":"Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Rabin Medical Center","has_results":false},{"nct_id":"NCT05837767","title":"A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue","phase":"NA","overall_status":"RECRUITING","enrollment_count":26,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT05383482","title":"Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"Laekna Limited","has_results":false},{"nct_id":"NCT03215810","title":"Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":true},{"nct_id":"NCT06599502","title":"A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":17,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07106827","title":"A Study of GV20-0251 in Advanced or Refractory Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT03811652","title":"A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"MedImmune LLC","has_results":false},{"nct_id":"NCT03041181","title":"Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Nasser Hanna, M.D.","has_results":true},{"nct_id":"NCT06090318","title":"Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss","phase":"PHASE1, PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Rain Oncology Inc","has_results":false}],"total":34},"guidelines":[],"source":"Drug Landscape verified database"}